InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

InMode Ltd. (Nasdaq: INMD), a prominent Israeli company specializing in innovative medical technologies, has announced its participation in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference. This year’s event is set to take place in Snowbird, Utah, on February 11, 2026. Yair Malca, the Chief Financial Officer of InMode, will host a series of investor meetings during the conference, providing a valuable opportunity for interested investors to engage with the company.

InMode is known for developing, manufacturing, and marketing cutting-edge devices that utilize advanced radiofrequency (RF) technology. The company aims to facilitate new surgical procedures while enhancing existing treatments across multiple medical categories, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. This diverse product portfolio positions InMode as a leader within the medical technology landscape, reflecting its commitment to driving innovation in minimally invasive solutions that can improve patient outcomes.

Investors looking to schedule meetings during the conference can reach out to their respective BTIG salesperson. For additional details about the event and the company, stakeholders are encouraged to visit InMode's investor relations website.

InMode continues to operate at the forefront of the medical technology sector, with its cutting-edge RF devices gaining recognition and acceptance in medical community practice. As the company prepares for this significant event, it underscores its ambition to connect with investors and showcase its contributions to advancing surgical techniques and healthcare solutions. For more information about InMode and its extensive array of medical technologies, visit their official website, www.inmodemd.com.

InMode Ltd. (Nasdaq: INMD) is set to participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference on February 11, 2026. This event will present a valuable opportunity for investors to engage directly with Chief Financial Officer Yair Malca, gaining insights into the company's strategic vision and financial health.

InMode is a key player in the medical technology space, specializing in innovative radiofrequency (RF) modalities. It caters to diverse sectors including plastic surgery, dermatology, and gynecology, which positions the company well to leverage the growing demand for minimally invasive treatment options. As the healthcare landscape evolves, demand for non-invasive procedures is increasing, suggesting a favorable market environment for InMode's product offerings.

Investors should consider the following factors when evaluating InMode's positioning:

1. **Market Trends**: The trend towards minimally invasive medical procedures continues to rise, driven by patient preference for less painful and quicker recovery options. InMode is strategically positioned to tap into this growing market, potentially leading to increased market share and revenue growth.

2. **Innovative Technology**: InMode's commitment to developing technology for emerging and existing surgical procedures speaks volumes about its potential for innovation and adaptability. The company's focus on research and development may yield new products that could enhance its competitive edge.

3. **Financial Performance**: While specifics about the company's current financial status are not detailed in the announcement, past performance metrics should be analyzed in the context of anticipated future growth. Investors are encouraged to review quarterly earnings reports and forward guidance from management, especially insights shared during the BTIG conference.

In summary, with a robust product lineup and a forward-thinking approach, InMode presents a compelling investment opportunity. Interested investors should consider attending the conference to gather valuable insights and evaluate the company's long-term prospects.